Galanis E - Search Results

1

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Sarkaria JN, et al. Among authors: galanis e. Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Neuro Oncol. 2018. PMID: 29016900 Free PMC article. Review.

2

Phase II trial of gemcitabine in advanced sarcomas.

Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Okuno S, et al. Among authors: galanis e. Cancer. 2002 Jun 15;94(12):3225-9. doi: 10.1002/cncr.10602. Cancer. 2002. PMID: 12115355 Free article. Clinical Trial.

3

Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.

Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Phuong LK, et al. Cancer Res. 2003 May 15;63(10):2462-9. Cancer Res. 2003. PMID: 12750267

4

Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.

Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Allen C, et al. Among authors: galanis e. J Gene Med. 2004 Nov;6(11):1216-27. doi: 10.1002/jgm.616. J Gene Med. 2004. PMID: 15459967

5

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Giannini C, et al. Among authors: galanis e. Neuro Oncol. 2005 Apr;7(2):164-76. doi: 10.1215/S1152851704000821. Neuro Oncol. 2005. PMID: 15831234 Free PMC article.

6

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ; North Central Cancer Treatment Group. Galanis E, et al. J Clin Oncol. 2005 Aug 10;23(23):5294-304. doi: 10.1200/JCO.2005.23.622. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998902 Clinical Trial.

7

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Galanis E, et al. Invest New Drugs. 2005 Oct;23(5):495-503. doi: 10.1007/s10637-005-2910-4. Invest New Drugs. 2005. PMID: 16133802 Clinical Trial.

8

Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.

Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV, Erickson BJ. Galanis E, et al. Neuro Oncol. 2006 Apr;8(2):156-65. doi: 10.1215/15228517-2005-005. Epub 2006 Mar 2. Neuro Oncol. 2006. PMID: 16533757 Free PMC article.

9

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.

Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Allen C, et al. Among authors: galanis e. Cancer Res. 2006 Dec 15;66(24):11840-50. doi: 10.1158/0008-5472.CAN-06-1200. Cancer Res. 2006. PMID: 17178881

10

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.

Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Sarkaria JN, et al. Among authors: galanis e. Mol Cancer Ther. 2007 Mar;6(3):1167-74. doi: 10.1158/1535-7163.MCT-06-0691. Mol Cancer Ther. 2007. PMID: 17363510

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

348 results

Search Page